Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 21;140(3):285-289.
doi: 10.1182/blood.2022015832.

Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

Amer M Zeidan  1   2 , Pierre Fenaux  3 , Marco Gobbi  4 , Jiří Mayer  5 , Gail J Roboz  6   7 , Jürgen Krauter  8 , Tadeusz Robak  9 , Hagop M Kantarjian  10 , Jan Novák  11 , Wieslaw W Jedrzejczak  12 , Xavier Thomas  13 , Mario Ojeda-Uribe  14 , Yasushi Miyazaki  15 , Yoo Hong Min  16 , Su-Peng Yeh  17 , Joseph M Brandwein  18 , Liana Gercheva  19 , Judit Demeter  20 , Elizabeth A Griffiths  21 , Karen W L Yee  22 , Jean-Pierre J Issa  23 , Jan Philipp Bewersdorf  1   2   24 , Harold Keer  25 , Yong Hao  25 , Mohammad Azab  25 , Hartmut Döhner  26
Affiliations

Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

Amer M Zeidan et al. Blood. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Survival outcomes for patients treated with AZA and DEC. (A) Treatment with AZA and DEC did not result in a statistically significant difference in terms of median, 1-year, or 2-year OS from the date of randomization. (B-C) OS by clinical (B) and major genetic (C) subgroups; hazard ratios (HRs) with 95% confidence intervals (CIs) for various clinical (B) and major genetic (C) subgroups are shown. All CIs included the null effect, suggesting that survival outcomes were similar in all analyzed clinical (B) and major genetic (C) subgroups. BM, bone marrow; LCL, lower confidence limit; UCL, upper confidence limit; WBC, white blood cell.
See this image and copyright information in PMC

References

    1. DiNardo CD, Jonas BA, Pullarkat V, et al. . Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383(7):617-629. - PubMed
    1. Wei AH, Montesinos P, Ivanov V, et al. . Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137-2145. - PMC - PubMed
    1. Dombret H, Seymour JF, Butrym A, et al. . International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291-299. - PMC - PubMed
    1. Kantarjian HM, Thomas XG, Dmoszynska A, et al. . Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670-2677. - PMC - PubMed
    1. Zeidan AM, Wang R, Wang X, et al. . Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Adv. 2020;4(10):2192-2201. - PMC - PubMed

MeSH terms